Ellisa JD - Clearpoint Neuro General Secretary

Clearpoint Neuro Management Efficiency

The company has return on total asset (ROA) of (0.2804) % which means that it has lost $0.2804 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6836) %, meaning that it created substantial loss on money invested by shareholders. Clearpoint Neuro's management efficiency ratios could be used to measure how well Clearpoint Neuro manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.5 in 2025. Return On Capital Employed is likely to drop to -0.77 in 2025. At this time, Clearpoint Neuro's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 1.6 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 4.7 M in 2025.

Similar Executives

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California. Clearpoint Neuro operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 80 people. Clearpoint Neuro (CLPT) is traded on NASDAQ Exchange in USA. It is located in 120 S. Sierra Avenue, Solana Beach, CA, United States, 92075 and employs 107 people. Clearpoint Neuro is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Clearpoint Neuro Leadership Team

Clearpoint Stock Performance Indicators

Additional Tools for Clearpoint Stock Analysis